Table 3.

The descriptive analysis of NIV modalities (HFNC–NIPPV).

	NIPPV	HFNC	o		NIPPV	HFNC	p
Age (months)*	27 (1.5–204)	14 (1.5–192)	0.002	Bodyweight (kg)*	10.5 (3–120)	9 (2.1–100)	0.004
Infanthood	46 (36.8%)	106 (46.7%)		NIV duration (hours)*	72 (6–480)	52 (6–48024)	0.012
Toddlers/preschool age	36 (28.8%)	83 (36.6%)	0.001	Previous intubation (hours)*	140 (28–726)	48 (25–1000)	< 0.001
School age/adolescents	43 (34.4%)	38 (16.7%)		PRISM-3 score*	6 (2–38)	5 (2–51)	0.264
Male gender, (n)	72 (57.6%)	128 (56.4%)	0.826	PELOD score*	6 (2–31)	8 (2–50)	0.240
Acute onset of disease				Underlying chronic conditions
LRTI	76 (60.8%)	91 (40.1%)	< 0.001	Cardiac disease	19 (15.2%)	71 (31.1%)	0.001
Bronchiolitis/asthma	43 (34.4%)	108 (47.6 %)	0.017	Neurological condition	33 (26.4%)	44 (19.4%)	0.128
URTI	-	11 (4.8%)	0.012	Metabolic disease	12 (9.6%)	10 (4.4%)	0.054
Postoperative stridor	4 (3.2%)	8 (3.5%)	0.569	Genetic disease	6 (4.8%)	13 (5.7%)	0.713
ARDS	10 (8%)	3 (1.3%)	0.001	Respiratory disease	13 (10.4%)	7 (3.1%)	0.005
Heart failure	10 (8%)	31 (13.7%)	0.113	Genitourinary disease	6 (4.8%)	10 (4.4%)	0.865
Sepsis	10 (8.8%)	19 (8.4%)	0.894	Gastrointestinal disease	3 (2.4%)	6 (2.6%)	0.896
CNS-related	5 (4%)	16 (7%)	0.248	Malignancy	7 (5.6%)	4 (1.8%)	0.048
				Immune deficiency	14 (11.2%)	11 (4.8%)	0.026
Outcome
PICU stay (days)*	11 (2–98)	7 (2–69)	< 0.001	Hospital discharge (days)*	20 (5–98)	12 (4–95)	< 0.001
Tracheostomy (n)	10 (8%)	6 (2.6%)	0.021	Exitus, (n)	8 (6.4%)	7 (3.1%)	0.140